203 related articles for article (PubMed ID: 27178334)
1. A novel subtype classification and risk of breast cancer by histone modification profiling.
Chen X; Hu H; He L; Yu X; Liu X; Zhong R; Shu M
Breast Cancer Res Treat; 2016 Jun; 157(2):267-279. PubMed ID: 27178334
[TBL] [Abstract][Full Text] [Related]
2. Histone modification profiling in breast cancer cell lines highlights commonalities and differences among subtypes.
Xi Y; Shi J; Li W; Tanaka K; Allton KL; Richardson D; Li J; Franco HL; Nagari A; Malladi VS; Coletta LD; Simper MS; Keyomarsi K; Shen J; Bedford MT; Shi X; Barton MC; Kraus WL; Li W; Dent SYR
BMC Genomics; 2018 Feb; 19(1):150. PubMed ID: 29458327
[TBL] [Abstract][Full Text] [Related]
3. Comparative epigenetic analyses reveal distinct patterns of oncogenic pathways activation in breast cancer subtypes.
Li Y; Li S; Chen J; Shao T; Jiang C; Wang Y; Chen H; Xu J; Li X
Hum Mol Genet; 2014 Oct; 23(20):5378-93. PubMed ID: 24871326
[TBL] [Abstract][Full Text] [Related]
4. Global analysis of H3K4me3 and H3K27me3 profiles in glioblastoma stem cells and identification of SLC17A7 as a bivalent tumor suppressor gene.
Lin B; Lee H; Yoon JG; Madan A; Wayner E; Tonning S; Hothi P; Schroeder B; Ulasov I; Foltz G; Hood L; Cobbs C
Oncotarget; 2015 Mar; 6(7):5369-81. PubMed ID: 25749033
[TBL] [Abstract][Full Text] [Related]
5. The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma.
Montes de Oca R; Gurard-Levin ZA; Berger F; Rehman H; Martel E; Corpet A; de Koning L; Vassias I; Wilson LO; Meseure D; Reyal F; Savignoni A; Asselain B; Sastre-Garau X; Almouzni G
Mol Oncol; 2015 Mar; 9(3):657-74. PubMed ID: 25497280
[TBL] [Abstract][Full Text] [Related]
6. Analysis of H3K4me3 and H3K27me3 bivalent promotors in HER2+ breast cancer cell lines reveals variations depending on estrogen receptor status and significantly correlates with gene expression.
Kaukonen D; Kaukonen R; Polit L; Hennessy BT; Lund R; Madden SF
BMC Med Genomics; 2020 Jul; 13(1):92. PubMed ID: 32620123
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive profiling of biological processes reveals two major prognostic subtypes in breast cancer.
Chen F; Gao S; Wang F; Ma J; Zhang M; Lv M; Zhou Q; Fu Z; Lu C; Yin H
Tumour Biol; 2016 Mar; 37(3):3365-70. PubMed ID: 26446459
[TBL] [Abstract][Full Text] [Related]
8. Competing endogenous RNA network analysis identifies critical genes among the different breast cancer subtypes.
Chen J; Xu J; Li Y; Zhang J; Chen H; Lu J; Wang Z; Zhao X; Xu K; Li Y; Li X; Zhang Y
Oncotarget; 2017 Feb; 8(6):10171-10184. PubMed ID: 28052038
[TBL] [Abstract][Full Text] [Related]
9. Integration of microRNA signatures of distinct mammary epithelial cell types with their gene expression and epigenetic portraits.
Pal B; Chen Y; Bert A; Hu Y; Sheridan JM; Beck T; Shi W; Satterley K; Jamieson P; Goodall GJ; Lindeman GJ; Smyth GK; Visvader JE
Breast Cancer Res; 2015 Jun; 17(1):85. PubMed ID: 26080807
[TBL] [Abstract][Full Text] [Related]
10. H3K4 acetylation, H3K9 acetylation and H3K27 methylation in breast tumor molecular subtypes.
Judes G; Dagdemir A; Karsli-Ceppioglu S; Lebert A; Echegut M; Ngollo M; Bignon YJ; Penault-Llorca F; Bernard-Gallon D
Epigenomics; 2016 Jul; 8(7):909-24. PubMed ID: 27424567
[TBL] [Abstract][Full Text] [Related]
11. Gene expression patterns associated with p53 status in breast cancer.
Troester MA; Herschkowitz JI; Oh DS; He X; Hoadley KA; Barbier CS; Perou CM
BMC Cancer; 2006 Dec; 6():276. PubMed ID: 17150101
[TBL] [Abstract][Full Text] [Related]
12. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.
Sørlie T; Wang Y; Xiao C; Johnsen H; Naume B; Samaha RR; Børresen-Dale AL
BMC Genomics; 2006 May; 7():127. PubMed ID: 16729877
[TBL] [Abstract][Full Text] [Related]
13. Investigation of genes and pathways involved in breast cancer subtypes through gene expression meta-analysis.
Jafarinejad-Farsangi S; Moazzam-Jazi M; Naderi Ghale-Noie Z; Askari N; Miri Karam Z; Mollazadeh S; Hadizadeh M
Gene; 2022 May; 821():146328. PubMed ID: 35181505
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes.
Nagel JH; Peeters JK; Smid M; Sieuwerts AM; Wasielewski M; de Weerd V; Trapman-Jansen AM; van den Ouweland A; Brüggenwirth H; van I Jcken WF; Klijn JG; van der Spek PJ; Foekens JA; Martens JW; Schutte M; Meijers-Heijboer H
Breast Cancer Res Treat; 2012 Apr; 132(2):439-48. PubMed ID: 21614566
[TBL] [Abstract][Full Text] [Related]
15. Oncofetal Epigenetic Bivalency in Breast Cancer Cells: H3K4 and H3K27 Tri-Methylation as a Biomarker for Phenotypic Plasticity.
Messier TL; Boyd JR; Gordon JA; Stein JL; Lian JB; Stein GS
J Cell Physiol; 2016 Nov; 231(11):2474-81. PubMed ID: 26916849
[TBL] [Abstract][Full Text] [Related]
16. Epigenetically maintained SW13+ and SW13- subtypes have different oncogenic potential and convert with HDAC1 inhibition.
Davis MR; Daggett JJ; Pascual AS; Lam JM; Leyva KJ; Cooper KE; Hull EE
BMC Cancer; 2016 May; 16():316. PubMed ID: 27188282
[TBL] [Abstract][Full Text] [Related]
17. Global histone modification profiling reveals the epigenomic dynamics during malignant transformation in a four-stage breast cancer model.
Zhao QY; Lei PJ; Zhang X; Zheng JY; Wang HY; Zhao J; Li YM; Ye M; Li L; Wei G; Wu M
Clin Epigenetics; 2016; 8():34. PubMed ID: 27034728
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic Modifications with DZNep, NaBu and SAHA in Luminal and Mesenchymal-like Breast Cancer Subtype Cells.
Dagdemir A; Judes G; Lebert A; Echegut M; Karsli-Ceppioglu S; Rifaï K; Daures M; Ngollo M; Dubois L; Penault-Llorca F; Bignon YJ; Bernard-Gallon D
Cancer Genomics Proteomics; 2016; 13(4):291-303. PubMed ID: 27365379
[TBL] [Abstract][Full Text] [Related]
19. The Epigenetic Landscape of Promoter Genome-wide Analysis in Breast Cancer.
Karsli-Ceppioglu S; Dagdemir A; Judes G; Lebert A; Penault-Llorca F; Bignon YJ; Bernard-Gallon D
Sci Rep; 2017 Jul; 7(1):6597. PubMed ID: 28747748
[TBL] [Abstract][Full Text] [Related]
20. The hyper-activation of transcriptional enhancers in breast cancer.
Li QL; Wang DY; Ju LG; Yao J; Gao C; Lei PJ; Li LY; Zhao XL; Wu M
Clin Epigenetics; 2019 Mar; 11(1):48. PubMed ID: 30867030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
